A Comprehensive Monograph on Hydroxychloroquine (DB01611)

Introduction: The Enduring and Evolving Role of a 4-Aminoquinoline

Hydroxychloroquine (HCQ) is a synthetic 4-aminoquinoline drug that occupies a unique and significant position in modern medicine.[1] Its development during World War II was driven by the need for antimalarial agents with a more favorable safety profile than earlier compounds like quinacrine and its direct chemical parent, chloroquine.[3] A serendipitous discovery during its widespread use revealed its profound immunomodulatory properties, a finding that fundamentally altered its clinical trajectory.[4] This led to its repurposing and eventual establishment as a cornerstone therapy in the management of chronic autoimmune diseases, most notably Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).[1]

The drug's clinical utility is defined by a dual identity: it functions as both an anti-infective agent for specific malarial parasites and as a Disease-Modifying Antirheumatic Drug (DMARD) capable of regulating the underlying processes of autoimmune conditions rather than merely palliating symptoms.[2] Its profound impact on patient outcomes, particularly in lupus, and its broad utility have secured its place on the World Health Organization's List of Essential Medicines.[1] Its extensive use is reflected in its prescription volume, ranking as the 112th most commonly prescribed medication in the United States in 2022 with over 5 million prescriptions filled.[1]

A central theme that governs the pharmacology, therapeutic application, and toxicology of hydroxychloroquine is its distinct pharmacokinetic profile. The drug is characterized by slow, cumulative tissue sequestration and an exceptionally long elimination half-life.[1] This behavior explains its delayed onset of therapeutic action in rheumatic diseases, dictates its dosing strategies, and is the primary driver of its most significant and feared cumulative toxicity: irreversible retinopathy. This creates a complex benefit-risk paradox. While developed to be acutely safer than chloroquine, its modern application in long-term, chronic therapy introduces an insidious risk that was not a primary consideration in its original, short-term antimalarial context. Understanding this paradox is fundamental to its safe and effective use.

More recently, hydroxychloroquine was thrust into the global spotlight during the COVID-19 pandemic. Its potential as a repurposed antiviral agent was intensely investigated, leading to an unprecedented intersection of preliminary science, clinical trial rigor, regulatory action, and public discourse.[3] The ultimate conclusion that it lacked efficacy for this indication provides a powerful modern case study on the principles of evidence-based medicine and the challenges of drug development in a public health crisis.[11] This report provides a comprehensive monograph on hydroxychloroquine, synthesizing evidence on its chemical nature, mechanisms of action, clinical applications, safety profile, and regulatory history.

Physicochemical Properties and Formulation

A precise understanding of hydroxychloroquine's chemical and physical properties is foundational to comprehending its biological activity and pharmaceutical formulation.

Chemical Identification and Nomenclature

Hydroxychloroquine is a small molecule drug belonging to the 4-aminoquinoline class.[1] It is classified as an organochlorine compound, a primary alcohol, a secondary amino compound, and a tertiary amino compound, and is functionally related to chloroquine.[3] Its unambiguous identification across scientific and regulatory databases is ensured by a comprehensive set of chemical identifiers.

Table 1: Comprehensive Drug Identifiers for Hydroxychloroquine

Identifier Type	Value	Source Snippet(s)
Drug Name	Hydroxychloroquine	1
DrugBank ID	DB01611	1
Type	Small Molecule	(User Query)
CAS Number	118-42-3	1
IUPAC Name	(RS)-2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol	1
Molecular Formula	C18​H26​ClN3​O	2
Molecular Weight	335.88 g/mol (base)	2
	433.95 g/mol (sulfate salt)	14
InChI	1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)	1
InChIKey	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	1
SMILES	OCCN(CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C)CC	3
PubChem CID	3652	1
ChEBI ID	CHEBI:5801	1
UNII	4QWG6N8QKH	1
KEGG ID	C07043, D08050	1

Structural Analysis

Hydroxychloroquine is chemically defined as an aminoquinoline that is chloroquine in which one of the N-ethyl groups on the side chain is hydroxylated at the terminal position (position 2).[2] This structural modification, the addition of a hydroxyl (-OH) group, is responsible for its altered pharmacokinetic and toxicity profile relative to chloroquine. The molecule possesses a chiral center and is manufactured and administered as a racemic mixture, containing equal parts of the (R) and (S) enantiomers.[3] This stereochemistry has implications for its biological activity, including differential binding to plasma proteins.[8]

Physical and Chemical Characteristics

The physical state of hydroxychloroquine is a solid.[3] As a sulfate salt, it appears as a white or practically white, crystalline powder [14], or a colorless crystalline solid.[16] Its solubility is highly dependent on its form. The sulfate salt is freely soluble in water but practically insoluble in organic solvents like alcohol, chloroform, and ether.[14] In contrast, the free base form is noted as being soluble in dimethyl sulfoxide (DMSO) but not in water, underscoring the necessity of the salt form for aqueous solubility and oral formulation.[13] The melting point of the base is reported to be in the range of 89-91 °C.[3]

A critical chemical property is its basicity. With a dissociation constant (pKa) of 9.67, hydroxychloroquine is a weak base.[3] This property is not merely a descriptive chemical fact; it is the direct driver of the drug's primary immunomodulatory mechanism. Because it is a weak base, it can readily diffuse across biological membranes in its uncharged state and subsequently become protonated and "trapped" within acidic intracellular compartments, a process known as ion-trapping.[7] This accumulation within acidic organelles like lysosomes is the initiating event for its complex effects on the immune system.

Formulations and Excipients

Hydroxychloroquine is administered orally, most commonly under the brand name Plaquenil, and is available as a generic medication.[1] It is formulated as hydroxychloroquine sulfate.[1] The standard tablet strength contains 200 mg of hydroxychloroquine sulfate, which is equivalent to 155 mg of the active hydroxychloroquine base.[14] This distinction between the weight of the salt and the active base is crucial for accurate dose calculations to ensure efficacy while minimizing the risk of toxicity. Other tablet strengths, such as 300 mg, are also available in some regions.[19] Inactive ingredients can vary by manufacturer but typically include fillers, binders, and coating agents such as lactose monohydrate, magnesium stearate, and titanium dioxide.[15]

Clinical Pharmacology: Mechanisms of Action

While the precise mechanisms of action for hydroxychloroquine are not entirely elucidated, extensive research has revealed a multi-faceted pharmacology that explains its efficacy in both infectious and autoimmune diseases.[16] These diverse effects largely stem from a single, fundamental physicochemical property: its ability as a weak base to accumulate in acidic intracellular vesicles.

Immunomodulatory Mechanisms

The drug's value in rheumatology is derived from its ability to modulate the immune system in several key ways.

Lysosomotropic Action and Inhibition of Antigen Presentation

This is considered the central mechanism of its immunomodulatory effect. As a weak base, hydroxychloroquine readily crosses cell membranes and becomes trapped within the acidic environment of intracellular organelles, particularly lysosomes and endosomes.[7] This accumulation, or lysosomotropic action, raises the internal pH of these vesicles.[8] Many of the enzymes responsible for processing antigens for presentation to the immune system are pH-dependent. By alkalinizing these compartments, hydroxychloroquine disrupts this machinery. Specifically, it inhibits the processing of antigens and prevents the proper dimerization of the alpha and beta chains of the Major Histocompatibility Complex (MHC) class II molecules.[8] This ultimately reduces the presentation of autoantigens on the surface of antigen-presenting cells, thereby dampening the activation of autoreactive T-cells that drive autoimmune diseases like lupus and rheumatoid arthritis.[8] It has been theorized that this effect may be somewhat selective, preferentially impairing the presentation of low-affinity self-peptides while allowing high-affinity foreign peptides to still be presented, which could help explain how it modulates autoimmunity without causing broad immunosuppression.[5]

Inhibition of Toll-Like Receptor (TLR) Signaling

A more specific and elegant mechanism involves the direct antagonism of endosomal Toll-Like Receptors (TLRs), particularly TLR7 and TLR9.[2] These receptors are critical components of the innate immune system that reside within endosomes and recognize nucleic acids (like single-stranded RNA for TLR7 and CpG DNA for TLR9) from pathogens or from damaged host cells.[4] In diseases like SLE, the activation of these TLRs by self-nucleic acids is a key pathogenic event, leading to the production of pro-inflammatory cytokines, most notably Type I interferons (e.g., interferon-alpha).[4] Hydroxychloroquine prevents this activation, likely by binding directly to the nucleic acids or interfering with receptor signaling within the endosome.[4] This blunts the cell-mediated inflammatory response and is strongly correlated with a reduction in interferon-alpha levels in patients, consistent with its powerful therapeutic effect in lupus.[4] This TLR-inhibition theory has largely displaced older, less specific hypotheses about general lysosomal disruption.[4]

Cytokine Modulation

Consistent with its other actions, hydroxychloroquine has been shown to reduce the production and release of key pro-inflammatory cytokines, including Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Tumor Necrosis Factor (TNF).[8] This contributes to its overall systemic anti-inflammatory effect.

Antimalarial Mechanism

The antimalarial action of hydroxychloroquine is thought to be similar to that of chloroquine and is also dependent on its accumulation in an acidic vesicle.[14] The

Plasmodium parasite digests the host's hemoglobin within its acidic food vacuole to obtain amino acids. This process releases large amounts of heme, which is toxic to the parasite. To protect itself, the parasite polymerizes the toxic heme into a non-toxic, crystalline form called hemozoin, a process mediated by the enzyme heme polymerase.[8] Hydroxychloroquine concentrates in the food vacuole, raises the pH, and is believed to inhibit heme polymerase, preventing the detoxification of heme.[8] The resulting accumulation of toxic free heme leads to oxidative damage and parasite death.[8]

Other Investigated Mechanisms

The fundamental action of hydroxychloroquine on lysosomes gives rise to other biological effects that are areas of active research.

• Autophagy Inhibition: Autophagy is a cellular "self-eating" process where damaged organelles and proteins are engulfed in autophagosomes, which then fuse with lysosomes for degradation. By raising lysosomal pH and preventing this fusion, hydroxychloroquine acts as an autophagy inhibitor.[7] This mechanism is being explored for its potential to sensitize cancer cells to apoptosis and is the basis for its investigation in oncology.[7]
• Antithrombotic Effects: Clinical studies in lupus patients have shown that hydroxychloroquine use is associated with a significant reduction in arterial thrombotic events.[4] This may be due to its ability to reduce levels of pathogenic antiphospholipid antibodies and interfere with antibody-mediated platelet activation.[4]
• Metabolic Effects: An unexpected but beneficial effect of hydroxychloroquine is its positive impact on metabolic profiles. Studies have reported significant reductions in total cholesterol and low-density lipoprotein (LDL-C) cholesterol, as well as lower average blood glucose levels in users.[4] These effects are particularly advantageous for patients with rheumatic diseases who may also be on corticosteroids, which can adversely affect metabolic parameters.[5]

The diverse biological activities of hydroxychloroquine are not disparate phenomena but are rather interconnected consequences of its fundamental physicochemical properties. The drug's ability to accumulate in and alkalinize acidic vesicles like lysosomes is the unifying event that explains its effects across rheumatology (disrupting antigen presentation and TLR signaling), malariology (inhibiting heme polymerization), and oncology (inhibiting autophagy). This provides a clear and cohesive understanding of how a single molecule can exert such a broad spectrum of action.

Pharmacokinetics: A Profile of Slow Accumulation and Elimination

The clinical behavior of hydroxychloroquine, including its delayed onset of action and its cumulative toxicity, is dictated by its unique pharmacokinetic profile. This profile is defined by extensive tissue distribution and an exceptionally slow rate of elimination.

Absorption

Following oral administration, hydroxychloroquine is readily absorbed from the gastrointestinal tract, with an average bioavailability estimated to be between 67% and 74%.[7] Peak blood and plasma concentrations are typically reached within 3 to 4 hours after a single dose.[8] Pharmacokinetic studies have demonstrated that its absorption follows linear kinetics over the therapeutic dose range, meaning that an increase in dose leads to a proportional increase in plasma concentration.[8]

Distribution

The most striking feature of hydroxychloroquine's pharmacokinetics is its massive volume of distribution (Vd​), estimated at approximately 44,257 liters when measured from plasma.[8] This exceptionally large value indicates that at any given time, the vast majority of the drug in the body is not in the bloodstream but is sequestered extensively within tissues.[7] This rapid partitioning into organs and deep tissue compartments is a key reason for its long duration of action and cumulative effects.[7]

• Tissue Accumulation: The drug's weak base properties cause it to become trapped and accumulate in acidic intracellular compartments like lysosomes across various tissues.[7] Furthermore, it demonstrates a high affinity for melanin-containing tissues, leading to significant accumulation in the skin and, most critically, in the retinal pigment epithelium of the eye.[7] This specific retinal accumulation is the basis for its dose-dependent ocular toxicity. Concentrations in tissues can be many times higher than those measured in plasma; for instance, brain concentrations can be 10 to 20 times greater than plasma levels.[20]
• Protein Binding: In the bloodstream, hydroxychloroquine is moderately bound to plasma proteins, with total binding estimated at around 50%.[8] It binds to both serum albumin and alpha-1-acid glycoprotein.[8] Studies have shown stereoselective differences in protein binding, with the (S) and (R) enantiomers exhibiting different affinities for these proteins.[8]

Metabolism

Hydroxychloroquine is metabolized in the liver, where it undergoes N-dealkylation primarily by the cytochrome P450 enzyme CYP3A4.[8] This process generates several metabolites, some of which are biologically active. The major metabolites identified in plasma and blood are desethylhydroxychloroquine (DHCQ), which is an active metabolite, and two inactive metabolites, desethylchloroquine (DCQ) and bidesethylhydroxychloroquine (BDCQ).[8]

Excretion

Elimination of hydroxychloroquine from the body is an extremely slow process, which is the primary reason for its very long half-life.

• Route of Elimination: The primary route of excretion is via the kidneys, with studies showing that approximately 23-25% of a dose is eliminated in the urine as the unchanged parent drug.[1] A smaller fraction, less than 10%, is eliminated through biliary excretion into the feces.[1]
• Half-Life (t1/2​): The terminal elimination half-life is the defining characteristic of hydroxychloroquine's pharmacokinetics. Following chronic administration, the half-life ranges from 40 to 50 days.[1] Some single-dose studies have reported even longer half-lives, up to 123.5 days in plasma.[8] This remarkably long duration is not due to inefficient renal or hepatic clearance but is a direct consequence of the slow, gradual release of the drug from the deep tissue compartments where it has accumulated.[15]

This pharmacokinetic profile creates a "pharmacological memory" within the body. Due to the extremely long half-life, it takes approximately 6 to 8 months for the drug to be fully eliminated after discontinuation. This persistence is confirmed by findings that drug levels are still detectable in urine three months after a single dose.[8] This has profound clinical implications. Most notably, it explains why the drug's most serious adverse effect, retinopathy, can continue to progress even after the medication has been stopped.[22] The retina acts as a deep reservoir, slowly leaking the drug and causing continued damage long after the last dose was ingested. This phenomenon makes managing toxicity challenging and renders concepts like a "drug holiday" infeasible.

Table 2: Summary of Key Pharmacokinetic Parameters for Hydroxychloroquine

Parameter	Value	Comments / Source Snippet(s)
Bioavailability (F)	67–74%	8
Time to Peak (Tmax​)	~3–4 hours	14
Volume of Distribution (Vd​)	~44,257 L (from plasma)	Extremely large, indicating extensive tissue sequestration.
Plasma Protein Binding	~50%	8
Primary Metabolizing Enzyme	CYP3A4	8
Major Active Metabolite	Desethylhydroxychloroquine (DHCQ)	8
Route of Elimination	Primarily renal (~25% unchanged)	1
Terminal Half-Life (t1/2​)	40–50 days	Exceptionally long due to slow release from tissues.

Clinical Indications, Efficacy, and Administration

Hydroxychloroquine is a prescription-only medication in most jurisdictions, including the United States, United Kingdom, Canada, and Australia.[1] It is approved for the treatment and prevention of malaria and for the treatment of specific autoimmune rheumatic diseases.

Rheumatoid Arthritis (RA)

In rheumatoid arthritis, hydroxychloroquine functions as a DMARD by regulating the overactive immune system, leading to a reduction in pain, swelling, and joint stiffness over the long term.[1] A key clinical characteristic is its delayed onset of action; patients may not notice significant benefits for up to 12 weeks, and a therapeutic trial of at least 6 months is often required before it can be deemed a failure.[2] It is frequently used in combination with other DMARDs, such as methotrexate, to achieve better disease control.[2] A significant advantage of hydroxychloroquine compared to some other DMARDs is its lack of myelosuppressive, hepatic, and renal toxicities, which simplifies monitoring.[2] However, studies have shown that long-term continuation rates in RA are lower than in lupus, often due to a lack of sustained efficacy rather than toxicity.[24]

Systemic and Discoid Lupus Erythematosus (SLE/DLE)

Hydroxychloroquine is considered a first-line, cornerstone therapy for all patients with SLE, regardless of disease severity.[1] Its benefits are profound and wide-ranging. It effectively treats many of the common manifestations of lupus, including cutaneous symptoms like skin rashes and mouth sores, musculoskeletal complaints like joint and muscle pain, and constitutional symptoms such as fatigue and fever.[5] It is also effective for serositis, such as pericarditis and pleuritis.[5]

Most importantly, its use is associated with significant improvements in long-term outcomes. Evidence from multiple studies indicates that hydroxychloroquine reduces the frequency of disease flares by as much as 50% and is associated with a mortality reduction of at least 50%.[4] It may also play a protective role by preventing the disease from spreading to and damaging major organs like the kidneys and central nervous system.[5] Due to these life-altering benefits, it is often referred to as "lupus life insurance," and many patients remain on the medication for life to maintain disease control.[5]

Malaria

Hydroxychloroquine is indicated for the prophylaxis (prevention) and treatment of acute attacks of malaria, but only in geographic areas where the Plasmodium parasites remain sensitive to chloroquine.[1] Its activity is limited to the erythrocytic (blood) stages of

Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and susceptible strains of Plasmodium falciparum.[8] It is not active against the gametocytes (the sexual forms of the parasite) or the exoerythrocytic forms, including the dormant hypnozoite stage in the liver associated with

P. vivax and P. ovale.[14] This means that for these species, hydroxychloroquine alone cannot provide a "radical cure" and must be combined with a drug active against the liver stage, such as an 8-aminoquinoline, to prevent relapse.[25]

Other and Investigational Uses

Hydroxychloroquine is also used for several other conditions:

• Porphyria Cutanea Tarda: An approved indication.[1]
• Q Fever: An infectious disease for which it is used in treatment.[1]
• Post-Lyme Arthritis: It is used in this condition, where it may have both anti-spirochete and anti-inflammatory activity.[1]
• Primary Sjögren Syndrome: While widely used, evidence suggests it is not effective for this condition.[1]
• Dementia Prevention: Emerging research from a large observational study of RA patients has linked hydroxychloroquine use with a significantly lower risk of developing Alzheimer's disease and related dementias. Preclinical models support this finding, showing that the drug can improve molecular signs of Alzheimer's pathology, such as reducing inflammation and enhancing the clearance of abnormal proteins.[26] This has positioned it as a promising candidate for future dementia prevention trials in high-risk individuals.
• Type 2 Diabetes Mellitus: A phase 1/2 clinical trial is currently investigating its potential influence on insulin secretion, building on observations of its hypoglycemic effects.[27]

Dosage and Administration

Dosing of hydroxychloroquine must be precise and individualized to maximize efficacy and minimize the risk of cumulative toxicity, particularly retinopathy. Doses are expressed in terms of the sulfate salt, and it is crucial to recognize that 200 mg of hydroxychloroquine sulfate is equivalent to 155 mg of the active base.[18] The medication should be taken with food or a glass of milk to reduce gastrointestinal upset.[18] Tablets should be swallowed whole and not crushed or divided, which can limit its use in pediatric patients below a certain body weight.[18]

Table 3: Dosage and Administration Guidelines for Hydroxychloroquine

Indication	Population	Dosing Regimen (Hydroxychloroquine Sulfate)	Maximum Dose	Key Comments	Source Snippet(s)
Malaria Prophylaxis	Adults	400 mg orally once weekly	400 mg/week	Start 1–2 weeks before travel, continue for 4 weeks after. Take on the same day each week.	18
	Pediatrics (≥31 kg)	6.5 mg/kg orally once weekly	400 mg/week	Dose based on actual body weight.	25
Malaria Treatment (Uncomplicated)	Adults	800 mg initial dose, then 400 mg at 6, 24, and 48 hours.	Total: 2000 mg	For chloroquine-sensitive strains only. Radical cure for P. vivax/ovale requires additional therapy.	18
	Pediatrics (≥31 kg)	13 mg/kg initial dose, then 6.5 mg/kg at 6, 24, and 48 hours.	Do not exceed adult dose.	Dose based on actual body weight.	25
Rheumatoid Arthritis	Adults	Initial: 400–600 mg/day (1–2 divided doses). Maintenance: 200–400 mg/day.	≤6.5 mg/kg/day or 600 mg/day (whichever is lower).	Onset may take months. Reduce to maintenance dose on response.	18
Systemic Lupus Erythematosus	Adults	200–400 mg/day (1–2 divided doses).	≤5 mg/kg/day (actual body weight) to minimize retinal risk.	Cornerstone therapy. Lifelong treatment often required.	25
JRA / Pediatric SLE	Pediatrics	3–5 mg/kg/day (1–2 divided doses).	400 mg/day	Used off-label; dose based on body weight. Safety/efficacy not formally established by FDA.	31

The COVID-19 Chapter: A Case Study in Drug Repurposing and Scientific Scrutiny

In early 2020, hydroxychloroquine became the subject of intense global focus as a potential treatment for the emerging coronavirus disease 2019 (COVID-19). This chapter in the drug's history serves as a critical case study in the process of drug repurposing, the hierarchy of scientific evidence, and the complex interplay between science, policy, and public perception during a pandemic.

The Scientific Rationale and Initial Enthusiasm

The investigation into hydroxychloroquine for COVID-19 was not without a plausible scientific basis. In vitro laboratory studies had demonstrated that the drug could inhibit the replication of SARS-CoV-2, the virus that causes COVID-19.[2] Furthermore, its known immunomodulatory properties, particularly its ability to suppress the production of pro-inflammatory cytokines like IL-6, suggested it might be beneficial in mitigating the severe inflammatory response, or "cytokine storm," that characterizes severe COVID-19 cases.[9]

This preclinical promise was amplified by early, small, and often non-randomized or poorly controlled clinical studies emerging from China and France, which reported positive outcomes.[10] These preliminary findings, combined with high-profile endorsements from public figures, ignited a firestorm of public interest and created immense pressure on regulatory bodies and healthcare systems to make the drug widely available.[10]

The Rise and Fall of the Emergency Use Authorization

In response to this pressure and the urgent need for therapies, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on March 28, 2020. This EUA allowed for the use of hydroxychloroquine from the Strategic National Stockpile to treat certain adult and adolescent patients hospitalized with COVID-19 for whom a clinical trial was not feasible.[9]

However, as the pandemic progressed, higher-quality evidence from large, well-designed, randomized controlled trials (RCTs) began to emerge. These trials, considered the gold standard for determining a drug's true efficacy, painted a starkly different picture. Two of the most influential trials, the United Kingdom's RECOVERY trial and the World Health Organization's multinational Solidarity Trial, independently and conclusively demonstrated that hydroxychloroquine provided no benefit to hospitalized patients with COVID-19.[11] Specifically, it did not reduce mortality or decrease the need for mechanical ventilation when compared to the standard of care.[11]

Based on this accumulating, high-quality evidence, the FDA took the decisive step of revoking the EUA for hydroxychloroquine on June 15, 2020.[3] The agency concluded that the drug was "unlikely to be effective" for treating COVID-19 and that, in light of its known risks (such as serious cardiac adverse events), its known and potential benefits no longer outweighed its known and potential risks for the authorized use.[9]

The Final Scientific Consensus

Subsequent RCTs investigating hydroxychloroquine in other settings, such as for early treatment of outpatients with mild-to-moderate COVID-19 or for post-exposure prophylaxis, also failed to demonstrate any clinical benefit.[35] The overwhelming scientific consensus, built upon the foundation of rigorous clinical trials, is that hydroxychloroquine is not an effective treatment for COVID-19 at any stage of the disease.

The episode serves as a powerful cautionary tale about the critical distinction between in vitro plausibility and in vivo clinical efficacy. While a drug may show promise in a laboratory setting, only large, randomized controlled trials can definitively establish its effectiveness and safety in the complex biological environment of the human body. The hydroxychloroquine-COVID-19 story underscores the indispensable role of this rigorous scientific process in guiding evidence-based medical practice and public health policy, particularly in times of crisis.

Comprehensive Safety Profile and Toxicology

Hydroxychloroquine possesses a narrow therapeutic index, meaning that the margin between a therapeutic dose and a toxic dose is small, necessitating careful dosing and monitoring.[1] Its adverse effects can be acute and transient, such as gastrointestinal upset, or chronic and cumulative, leading to irreversible organ damage.

Ocular Toxicity: The Primary Risk of Long-Term Therapy

The most serious and well-known adverse effect of long-term hydroxychloroquine therapy is irreversible retinal toxicity.

• Pathophysiology and Prevalence: The drug binds to melanin in the retinal pigment epithelium (RPE), leading to accumulation and subsequent damage to the RPE and the overlying photoreceptors.[7] This toxicity is directly related to the cumulative dose and duration of therapy.[1] Once considered rare, modern screening techniques have revealed a higher prevalence than previously understood. The risk is approximately 7.5% for individuals on long-term therapy, but this can increase dramatically to 20–50% after 20 years of continuous use.[21] The classic clinical sign is a "bull's eye maculopathy," a pattern of RPE atrophy surrounding the fovea, though other patterns can occur.[21] Critically, the damage may continue to progress even after the drug is discontinued due to its long persistence in retinal tissue.[22]
• Screening and Risk Management: Early detection is the only way to prevent severe, vision-threatening damage. The American Academy of Ophthalmology (AAO) and other professional bodies have established clear screening guidelines. The primary goal is to identify early, pre-symptomatic changes, as there is no treatment for established retinopathy.[22]

Table 4: Retinopathy Risk Factors and Screening Guidelines

Category	Detail	Source Snippet(s)
Major Risk Factors	Daily dose > 5 mg/kg (of actual body weight)	14
	Duration of use > 5 years	21
	Significant renal disease (impaired GFR)	14
	Concomitant tamoxifen use	14
	Pre-existing retinal or macular disease	21
Screening Protocol	Baseline Exam (within 1st year of starting): A comprehensive eye exam including fundus photography, Spectral-Domain Optical Coherence Tomography (SD-OCT), and an automated visual field test (e.g., 10-2 Humphrey Visual Field).	21
	Annual Screening: Recommended to begin after 5 years of use for patients without major risk factors. For patients with one or more major risk factors, annual screening should begin sooner, potentially after the first year of therapy.	21
	Essential Annual Tests: SD-OCT and automated visual fields are the primary screening tools for detecting early toxicity. Fundus autofluorescence (FAF) is also highly recommended.	21
Action	If definitive signs of retinopathy are detected, the prescribing physician must be notified immediately with a recommendation to discontinue hydroxychloroquine.	21

Cardiotoxicity

Fatal and life-threatening cardiotoxicity, including cardiomyopathy, has been reported with both acute and chronic use of hydroxychloroquine.[1] Patients may present with signs of heart failure or conduction disorders.[30] Additionally, hydroxychloroquine has a known potential to prolong the QT interval on an electrocardiogram (ECG).[14] This can increase the risk of developing life-threatening ventricular arrhythmias, including Torsades de Pointes, especially when the recommended dose is exceeded or when it is co-administered with other QT-prolonging medications like amiodarone or certain antibiotics (e.g., azithromycin).[14]

Serious Skin Reactions

While rare, hydroxychloroquine can cause severe and potentially fatal cutaneous adverse reactions. These include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).[23] Patients should be advised to seek immediate medical attention for any new, severe, or blistering rash.

Neuropsychiatric Adverse Events

A wide spectrum of neuropsychiatric effects has been reported. Common effects include headache and dizziness.[1] More serious events, though less common, include agitation, insomnia, emotional lability, mania, psychosis, paranoia, depression, and suicidal ideation or behavior.[1] The drug's ability to cross the blood-brain barrier likely underlies these effects.[20]

Other Clinically Significant Adverse Effects

• Gastrointestinal: The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and abdominal cramps. These are often transient and can be mitigated by taking the medication with food or milk.[1]
• Hematologic: Periodic blood cell counts are recommended during prolonged therapy due to the risk of myelosuppression, which can manifest as aplastic anemia, agranulocytosis, or leukopenia.[23] In patients with a genetic deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD), hydroxychloroquine can trigger acute hemolytic anemia.[25]
• Musculoskeletal: Skeletal muscle myopathy or neuropathy can occur, leading to progressive weakness and atrophy, particularly of the proximal muscle groups.[30]
• Hypoglycemia: Hydroxychloroquine can cause severe and sometimes life-threatening hypoglycemia (low blood sugar), even in patients without diabetes. Patients, especially those on concomitant antidiabetic medications, should be warned of this risk and educated on the symptoms.[1]

Overdose

Overdose with 4-aminoquinoline compounds is extremely dangerous and can be rapidly fatal. Toxic symptoms can appear within 30 minutes of ingestion.[16] Symptoms include drowsiness, severe visual disturbances (which may be permanent), seizures, coma, cardiovascular collapse with rhythm and conduction disorders, and sudden respiratory and cardiac arrest.[1] Overdose is a medical emergency requiring immediate attention.

Contraindications, Precautions, and Drug Interactions

The safe use of hydroxychloroquine requires careful patient selection and awareness of its contraindications, necessary precautions, and potential for clinically significant drug interactions.

Contraindications

The use of hydroxychloroquine is absolutely contraindicated in the following situations:

• Patients with a known hypersensitivity to hydroxychloroquine or any other 4-aminoquinoline compound.[18]
• Patients with pre-existing retinal or visual field changes that are attributable to a 4-aminoquinoline compound.[23]
• Some drug labels list long-term therapy in children as a contraindication, although it is widely used off-label for pediatric rheumatic diseases under specialist care.[23]

Warnings and Precautions

Special caution is warranted in several patient populations:

• Psoriasis and Porphyria: Hydroxychloroquine may precipitate a severe attack of psoriasis or exacerbate porphyria. Its use should generally be avoided in patients with these conditions unless the potential benefit is judged to outweigh the risk.[2]
• Renal or Hepatic Impairment: Since the drug is metabolized by the liver and excreted by the kidneys, patients with impaired hepatic or renal function are at increased risk of drug accumulation and toxicity. Dose adjustments or more frequent monitoring may be necessary.[1]
• Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Patients with this genetic condition are at risk of developing hemolytic anemia when taking hydroxychloroquine and should be monitored accordingly.[25]
• Cardiac Disease: Patients with pre-existing heart disease, conduction disorders, or known risk factors for QT prolongation should use hydroxychloroquine with extreme caution due to the risk of cardiotoxicity.[30]
• Neurological Disorders: Caution is advised in patients with a history of seizures or other neurological disorders, as hydroxychloroquine may lower the seizure threshold.[30]

Clinically Significant Drug-Drug Interactions

Hydroxychloroquine's narrow therapeutic index and potential for serious adverse effects make a thorough review of concomitant medications essential.

Table 5: Clinically Significant Drug-Drug Interactions with Hydroxychloroquine

Interacting Drug/Class	Potential Effect	Mechanism	Clinical Management	Source Snippet(s)
QT-Prolonging Drugs (e.g., amiodarone, azithromycin, certain antipsychotics, cisapride)	Increased risk of life-threatening ventricular arrhythmias (Torsades de Pointes)	Additive effect on cardiac repolarization (QT interval prolongation)	Combination should be avoided. If unavoidable, perform baseline and periodic ECG monitoring.	14
Insulin & Oral Antidiabetic Drugs (e.g., metformin, sulfonylureas)	Enhanced hypoglycemic effect, risk of severe low blood sugar	Hydroxychloroquine has intrinsic glucose-lowering properties.	Increased blood glucose monitoring is required. Dose reduction of antidiabetic agents may be necessary. Patients should be educated on hypoglycemia symptoms.	1
Antiepileptic Drugs (e.g., carbamazepine, phenytoin, phenobarbital)	May lower the seizure threshold, potentially reducing the efficacy of antiepileptic drugs.	Unknown.	Use with caution. Monitor for seizure activity.	30
Digoxin	Increased plasma concentrations of digoxin, leading to toxicity.	Hydroxychloroquine may inhibit P-glycoprotein, a drug transporter responsible for digoxin clearance.	Monitor serum digoxin levels closely and for clinical signs of toxicity. Digoxin dose reduction may be needed.	1
Methotrexate	Co-administration has not been systematically studied, but there is a theoretical potential for increased adverse effects.	Both are immunomodulators used in RA.	Use with caution; this combination is common and generally considered safe in clinical practice for RA, but monitoring is prudent.	30
Cyclosporine	Increased blood levels of cyclosporine, increasing risk of toxicity (e.g., nephrotoxicity).	Unknown, likely inhibition of cyclosporine metabolism.	Monitor cyclosporine levels closely when initiating or discontinuing hydroxychloroquine.	30
Antacids & Kaolin	Markedly decreased absorption of hydroxychloroquine, leading to reduced efficacy.	Forms a non-absorbable complex with hydroxychloroquine in the GI tract.	Separate administration by at least 4 hours.	19
Cimetidine	Increased plasma concentration of hydroxychloroquine.	Cimetidine is an inhibitor of cytochrome P450 enzymes, which can reduce the metabolism of hydroxychloroquine.	Use with caution. Monitor for signs of hydroxychloroquine toxicity.	1

Use in Specific Populations

The benefit-risk assessment for hydroxychloroquine must be tailored to specific patient populations, including pregnant women, children, and the elderly.

Pregnancy and Lactation

• Pregnancy: Contrary to older concerns, current evidence strongly supports the safety and importance of continuing hydroxychloroquine during pregnancy for women with rheumatic diseases like SLE and RA.[1] The risks posed to the mother and fetus by uncontrolled maternal disease (e.g., lupus flares, which can cause premature birth and growth problems) are considered significantly greater than the risks from the medication.[41] A large, population-based cohort study published in 2025 found that first-trimester exposure to hydroxychloroquine was not associated with a significantly increased risk of major congenital malformations in the infant.[42] Therefore, discontinuation is generally not recommended.
• Lactation: Hydroxychloroquine passes into breast milk, but only in very small amounts.[41] International professional guidelines consider it a low-risk medication that is acceptable to use during breastfeeding.[43] Careful follow-up of breastfed infants has not revealed any adverse effects on growth, vision, or hearing.[43] The amount transferred is not sufficient to protect the infant from malaria.[43]

Pediatric Use

Hydroxychloroquine is used in children for specific indications.

• Malaria: It is approved for both prophylaxis and treatment of malaria in children, with dosing calculated based on body weight.[25] However, because the tablets are not designed to be crushed or divided, there is a minimum weight limit for its use (e.g., less than 31 kg for Plaquenil), below which accurate dosing is not possible.[18]
• Rheumatic Diseases: It is used off-label for the treatment of certain childhood rheumatic conditions, most commonly Juvenile Idiopathic Arthritis (JIA) and pediatric-onset SLE.[2] The typical dose is 3–5 mg/kg/day.[31] While effective, long-term use necessitates regular ophthalmologic monitoring, which can be challenging in very young children who may have difficulty with subjective vision tests.[32]

Geriatric Use

The use of hydroxychloroquine in elderly patients requires increased vigilance. Older adults are more likely to have pre-existing conditions that elevate their risk of toxicity, such as renal insufficiency (which impairs drug clearance) and underlying cardiac disease (which increases susceptibility to cardiotoxicity).[20] Furthermore, due to a longer lifetime of potential exposure, they are at a higher cumulative risk for developing retinopathy.[23] A clinical trial is currently underway to evaluate the safety of withdrawing hydroxychloroquine in stable SLE patients aged 60 and older, seeking to balance the escalating risk of retinal toxicity against the risk of a disease flare.[45] In a different context, emerging research has linked hydroxychloroquine use in elderly RA patients to a lower incidence of dementia, suggesting a potential future role in neuroprotection that requires further investigation.[26]

Conclusion and Future Directions

Hydroxychloroquine is a venerable drug whose journey from an antimalarial agent to a cornerstone of modern rheumatology highlights its unique and potent pharmacological properties. Its clinical value is undeniable, particularly in the management of Systemic Lupus Erythematosus, where it is a life-saving and mortality-reducing therapy. Its benefits as a disease-modifying agent in Rheumatoid Arthritis and other autoimmune conditions are also well-established.

However, the use of this powerful medication is intrinsically linked to a careful and continuous assessment of its significant, cumulative risks. The benefit-risk profile of hydroxychloroquine is dominated by the threat of irreversible retinopathy, a dose- and duration-dependent toxicity that mandates a rigorous program of risk stratification and ophthalmologic screening for all patients on long-term therapy. Other serious risks, including cardiotoxicity, severe skin reactions, and neuropsychiatric events, further underscore the need for vigilance. The key to its successful and safe clinical application lies in a triad of principles: meticulous patient selection, strict adherence to weight-based dosing guidelines (not to exceed 5 mg/kg of actual body weight per day), and unwavering commitment to long-term safety monitoring.

The intense but ultimately unsuccessful investigation of hydroxychloroquine for COVID-19 provided a stark, real-world lesson on the primacy of evidence. It reaffirmed that preclinical plausibility and early observational data, while useful for hypothesis generation, cannot replace the definitive evidence derived from large, randomized controlled trials in guiding clinical practice and regulatory policy.

Looking forward, several avenues of research hold promise. The most intriguing is the potential neuroprotective role of hydroxychloroquine and its investigation as a repurposed drug for the prevention of neurodegenerative diseases like Alzheimer's. Further research is also warranted to refine risk stratification for toxicity, potentially through the use of therapeutic drug monitoring or pharmacogenomic markers to identify patients at highest risk. Finally, ongoing studies, such as the trial evaluating the safety of hydroxychloroquine withdrawal in stable elderly lupus patients, will provide crucial data to help clinicians optimize long-term management strategies and further personalize the use of this enduringly important medication. The ultimate clinical recommendation is for a personalized, risk-aware approach, where clinicians treat hydroxychloroquine with the respect its potency and unique pharmacokinetic profile demand, ensuring its benefits can be realized while its risks are diligently mitigated over a patient's entire treatment lifetime.

Works cited

1. Hydroxychloroquine - Wikipedia, accessed July 14, 2025, https://en.wikipedia.org/wiki/Hydroxychloroquine
2. Hydroxychloroquine | 118-42-3 - ChemicalBook, accessed July 14, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6866802.htm
3. Hydroxychloroquine | C18H26ClN3O | CID 3652 - PubChem, accessed July 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/3652
4. Hydroxychloroquine: An old drug with new relevance | Cleveland ..., accessed July 14, 2025, https://www.ccjm.org/content/85/6/459
5. Treating Lupus with Anti-Malarial Drugs, accessed July 14, 2025, https://www.hopkinslupus.org/lupus-treatment/lupus-medications/antimalarial-drugs/
6. Hydroxychloroquine | Side-effects, uses, time to work - Versus Arthritis, accessed July 14, 2025, https://versusarthritis.org/about-arthritis/treatments/drugs/hydroxychloroquine/
7. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5931434/
8. Hydroxychloroquine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/drugs/DB01611
9. The Rise and Fall of Chloroquine/Hydroxychloroquine as ..., accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8134745/
10. Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID‐19 - PMC, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10845847/
11. Coronavirus disease (COVID-19): Solidarity Trial and ..., accessed July 14, 2025, https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-hydroxychloroquine
12. Registration Dossier - Hydroxychloroquine - ECHA, accessed July 14, 2025, https://echa.europa.eu/registration-dossier/-/registered-dossier/19270
13. Hydroxychloroquine free base | CAS#118-42-3 - MedKoo Biosciences, accessed July 14, 2025, https://www.medkoo.com/products/7397
14. hydroxychloroquine sulfate tablets, usp description - accessdata.fda.gov, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
15. Hydroxychloroquine Sulfate Tablets - accessdata.fda.gov, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201691Orig1s000lbl.pdf
16. PLAQUENIL® - accessdata.fda.gov, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf
17. Generic Plaquenil Availability - Drugs.com, accessed July 14, 2025, https://www.drugs.com/availability/generic-plaquenil.html
18. Hydroxychloroquine Dosage Guide + Max Dose, Adjustments ..., accessed July 14, 2025, https://www.drugs.com/dosage/hydroxychloroquine.html
19. How and when to take hydroxychloroquine - NHS, accessed July 14, 2025, https://www.nhs.uk/medicines/hydroxychloroquine/how-and-when-to-take-hydroxychloroquine/
20. The role of hydroxychloroquine sulfate in the geriatric patient with coronavirus disease 2019 (COVID-19). What is useful to know for the geriatrician?, accessed July 14, 2025, https://www.pagepressjournals.org/index.php/gc/article/view/9015/8803
21. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring - The Royal College of Ophthalmologists |, accessed July 14, 2025, https://www.rcophth.ac.uk/wp-content/uploads/2020/12/Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf
22. Hydroxychloroquine-Induced Retinal Toxicity - Patients - The ..., accessed July 14, 2025, https://www.asrs.org/patients/retinal-diseases/45/hydroxychloroquine-induced-retinal-toxicity
23. PLAQUENIL® HYDROXYCHLOROQUINE SULFATE - Sanofi U.S., accessed July 14, 2025, https://products.sanofi.us/plaquenil/plaquenil.pdf
24. Continuation of long term treatment with hydroxychloroquine in ..., accessed July 14, 2025, https://ard.bmj.com/content/51/12/1318
25. Hydroxychloroquine Uses, Dosage & Side Effects - Drugs.com, accessed July 14, 2025, https://www.drugs.com/hydroxychloroquine.html
26. Hydroxychloroquine lowers dementia risk in humans, improves ..., accessed July 14, 2025, https://www.alzheimers.gov/news/hydroxychloroquine-lowers-dementia-risk-humans-improves-molecular-signs-alzheimers-mouse-and
27. Hydroxychloroquine Unknown Status Phase 1 / 2 Trials for Type 2 Diabetes Mellitus Treatment | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/drugs/DB01611/clinical_trials?conditions=DBCOND0029752&phase=1%2C2&purpose=treatment&status=unknown_status
28. Plaquenil Dosage Guide - Drugs.com, accessed July 14, 2025, https://www.drugs.com/dosage/plaquenil.html
29. Hydroxychloroquine (oral route) - Mayo Clinic, accessed July 14, 2025, https://www.mayoclinic.org/drugs-supplements/hydroxychloroquine-oral-route/description/drg-20064216
30. This label may not be the latest approved by FDA. For current ..., accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/009768s053lbl.pdf
31. Hydroxychloroquine: Pediatric drug information - sniv3r2.github.io, accessed July 14, 2025, https://sniv3r2.github.io/d/topic.htm?path=hydroxychloroquine-pediatric-drug-information
32. Hydroxychloroquine (Plaquenil): Benefits, Side Effects, and Dosing - Lupus Foundation, accessed July 14, 2025, https://www.lupus.org/resources/drug-spotlight-on-hydroxychloroquine
33. hydroxychloroquine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 14, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198
34. Hydroxychloroquine sulfate EUA fact sheet for parent/caregivers - FDA, accessed July 14, 2025, https://www.fda.gov/media/136538/download
35. News: Hydroxychloroquine studies show drug... (The Washington Post) - Behind the headlines - NLM - NCBI, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/search/research-news/10704
36. Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19) | ClinicalTrials.gov, accessed July 14, 2025, https://clinicaltrials.gov/study/NCT04466540
37. Taking hydroxychloroquine with other medicines and herbal supplements - NHS, accessed July 14, 2025, https://www.nhs.uk/medicines/hydroxychloroquine/taking-hydroxychloroquine-with-other-medicines-and-herbal-supplements/
38. Hydroxychloroquine: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 14, 2025, https://www.webmd.com/drugs/2/drug-5482/hydroxychloroquine-oral/details
39. Hydroxychloroquine: MedlinePlus Drug Information, accessed July 14, 2025, https://medlineplus.gov/druginfo/meds/a601240.html
40. Hydroxychloroquine: Uses, Interactions & Side Effects - Cleveland Clinic, accessed July 14, 2025, https://my.clevelandclinic.org/health/drugs/19772-hydroxychloroquine-tablets
41. Pregnancy, breastfeeding and fertility while taking ... - NHS, accessed July 14, 2025, https://www.nhs.uk/medicines/hydroxychloroquine/pregnancy-breastfeeding-and-fertility-while-taking-hydroxychloroquine/
42. Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study - Oxford Academic, accessed July 14, 2025, https://academic.oup.com/rheumatology/article-abstract/64/1/117/7628323
43. Hydroxychloroquine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501150/
44. Hydroxychloroquine (children) - Arthritis Australia, accessed July 14, 2025, https://arthritisaustralia.com.au/medication-search/hydroxychloroquine-children/
45. Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | UCLA Health Clinical Trials and Research Studies, accessed July 14, 2025, https://www.uclahealth.org/clinical-trials/effects-stopping-hydroxychloroquine-elderly-lupus-disease